Literature DB >> 1329491

The dysphoria of heroin addiction.

L Handelsman1, M J Aronson, R Ness, K J Cochrane, P D Kanof.   

Abstract

Levels of dysphoria and opioid dependence were assessed in 54 male patients with heroin addiction applying for drug treatment. During a period of naturalistic heroin use, symptom measures of dysphoria and of spontaneous opioid withdrawal reported by these patients were highly correlated. Upon admission to treatment, levels of dysphoria and opioid withdrawal were assessed before and after a pharmacological challenge with either 0.4 mg naloxone or placebo. Signs and symptoms of opioid withdrawal and symptoms of dysphoria increased in patients following naloxone, but not placebo administration. Naloxone-induced changes in symptoms of dysphoria were correlated with changes in opioid withdrawal as assessed by both subjective and objective measures. These findings suggest that dysphoric mood states in heroin addicts may be, in part, pharmacological sequelae of their drug dependence. Dysphoria due to opioid withdrawal may contribute to the initiation and maintenance of heroin use, and to the high rates of syndromal affective disorders reported in this population.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329491     DOI: 10.3109/00952999209026067

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  11 in total

1.  Self-reported Sleep Improvement in Buprenorphine MAT (Medication Assisted Treatment) Population.

Authors:  W H Zheng; R J Wakim; R C Geary; L R Lander; S J Wen; M C Xiao; C R Sullivan
Journal:  Austin J Drug Abuse Addict       Date:  2016-07-25

2.  The added risk of opioid problem use among treatment-seeking youth with marijuana and/or alcohol problem use.

Authors:  Geetha A Subramaniam; Melissa L Ives; Maxine L Stitzer; Michael L Dennis
Journal:  Addiction       Date:  2010-04       Impact factor: 6.526

Review 3.  Changing mechanisms of opiate tolerance and withdrawal during early development: animal models of the human experience.

Authors:  Gordon A Barr; Anika McPhie-Lalmansingh; Jessica Perez; Michelle Riley
Journal:  ILAR J       Date:  2011

4.  Sex differences in affective response to opioid withdrawal during adolescence.

Authors:  Stephen R Hodgson; Rebecca S Hofford; Kris W Roberts; Dvora Eitan; Paul J Wellman; Shoshana Eitan
Journal:  J Psychopharmacol       Date:  2009-11-25       Impact factor: 4.153

5.  Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence.

Authors:  Angela J Dean; John B Saunders; Rod T Jones; Ross M Young; Jason P Connor; Bruce R Lawford
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

6.  Different affective response to opioid withdrawal in adolescent and adult mice.

Authors:  Stephen R Hodgson; Rebecca S Hofford; Paul J Wellman; Shoshana Eitan
Journal:  Life Sci       Date:  2008-11-12       Impact factor: 5.037

7.  Extended-release formulation of morphine for subcutaneous administration.

Authors:  T Kim; J Kim; S Kim
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  [The neurobiology of anhedonia. The pathophysiology of an important symptom in depressive disorders].

Authors:  S R Kuhlmann; H Walter; T E Schläpfer
Journal:  Nervenarzt       Date:  2013-05       Impact factor: 1.214

Review 9.  Anhedonia, Hyperkatifeia, and Negative Reinforcement in Substance Use Disorders.

Authors:  George F Koob
Journal:  Curr Top Behav Neurosci       Date:  2022

10.  Behavioral architecture of opioid reward and aversion in C57BL/6 substrains.

Authors:  Stacey L Kirkpatrick; Camron D Bryant
Journal:  Front Behav Neurosci       Date:  2015-01-12       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.